Optimizing Response to Phosphodiesterase Therapy: Impact of Risk-Factor Management

Journal of Andrology

Volumn 24, Issue 6 SUPPL., 2003, Pages

  Guay, André T ^a  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; UNCLASSIFIED DRUG;

ANXIETY; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DIABETES CONTROL; DIABETES MELLITUS; ERECTILE DYSFUNCTION; FEAR; HUMAN; IMPOTENCE; MALE; OBESITY; PATIENT SATISFACTION; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; PSYCHOTHERAPIST; RISK FACTOR; SEX THERAPY; TREATMENT OUTCOME;

EID: 0242457470     PISSN: 01963635     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1939-4640.2003.tb02748.x     Document Type: Conference Paper

References (31)

1. AACE Clinical Practice Guidelines For The Evaluation And Treatment Of Male Sexual Dysfunction. Endocr Pract. 1998;4:219-235.
2. Althof SE, Corty EW, Levine SB, et al. EDITS: development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction. Urology. 1999;53:793-799.
3. Barada J. Successful salvage of sildenafil (Viagra) failures: benefits of patient education and rechallenge with sildenafil. Int J Impot Res. 2001;13(suppl 4):S49.
4. Carrier S, Zvara P, Lue TF. Erectile dysfunction. Endocrinol Metab Clin North Am. 1994;23:773-782.
5. Chew KK, Earle CM, Stuckey BGA, et al. Erectile dysfunction in general medical practice: prevalence and clinical correlates. Int J Impot Res. 2000;12:41-45.
6. Derby CA, Mohr BA, Goldstein I, et al. Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology. 2000;56:302-306.
7. Fawzy A. Practice patterns of primary care physicians in management of erectile dysfunction. Int J Impot Res. 2000;12(suppl 3):B10.
8. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychological correlates: results of the Massachusetts Male Aging study. J Urol. 1994;151:54-61.
9. Feldman HA, Johannes CB, Derby CA. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts Male Aging Study. Prev Med. 2000;30:328-338.
10. Guay AT, Jacobson J. Improvement in erectile dysfunction by correction of elevated cholesterol levels [abstract]. Int J Impot Res. 2002;14(suppl 3):S105-S106.
11. Guay AT, Perez JB, Jacobson J, Newton RA. Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors. J Androl. 2001;22:793-797.
12. Guay AT, Velasquez E, Perez JB. Characterization of patients in a medical endocrine-based center for male sexual dysfunction. Endocr Pract. 1999;5:314-321.
13. Lewis RB, Bennett CJ, Borkon WD, et al. Patient and partner satisfaction with Viagra (sildenafil citrate) treatment as determined by the erectile dysfunction inventory of treatment satisfaction questionnaire. Urology. 2001;57:960-965.
14. Lue TF, Donatucci CF. Dysfunction of the venoocclusive mechanism. In: Bennett AH, ed. Impotence: Diagnosis and Management of Erectile Dysfunction. Philadelphia, Pa: WB Saunders; 1994:197-204.
15. McCullough AR, Barada JH, Fawzy A, et al. Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction. Urology. 2002;60(suppl 2B):28-38.
16. Moreland RB. Pathophysiology of erectile dysfunction: the contributions of trabecular structure to function and the role of functional antagonism. Int J Impot Res. 2000;12(suppl 4):S39-S46.
17. NIH Consensus Development Panel on Impotence. NIH Consensus Conference. Impotence. JAMA. 1993;270:83-90.
18. Nurnberg HG, Hensley PL, Geleberg AJ, et al. Treatment of antidepressant-associated sexual dysfunction with sildenafil. JAMA. 2003;289:56-64.
19. Paige NM, Hays RD, Litwin MS, et al. Improvement in emotional well-being and relationships of users of sildenafil. J Urol. 2001;166:1774-1778.
20. Pickard RS, Powell PH, Zar MA. Nitric oxide and cyclic GMP formation following relaxant nerve stimulation in isolated human corpus cavernosum. Br J Urol. 1995;75:516-522.
21. Pritzker MR. The penile stress test: a window to the hearts of man? [abstract]. Circulation. 1999;100(suppl 1):3751.
22. Rajfer J, Aronson WJ, Bush PA, et al. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med. 1992;326:90-94.
23. Rosen RC, Cappelleri JC, Smith MD, et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999;11:319-326.
24. Seftel AD. Challenges in oral therapy for erectile dysfunction. J Androl. 2002;23:729-736.
25. Sharlip ID. Vasculogenic impotence secondary to atherosclerosis/dysplasia. In: Bennett AH, ed. Impotence: Diagnosis and Management of Erectile Dysfunction. Philadelphia, Pa: WB Saunders; 1994:205-212.
26. Slag MF, Morley JE, Elson MK, et al. Impotence in medical clinic outpatients. JAMA. 1983;249:1736-1740.
27. Spark RF, White RA, Connolly PB. Impotence is not always psychogenic: newer insights into hypothalamic-pituitary-gonadal dysfunction. JAMA. 1980;243:750-755.
28. Spark RF, Wills CA, Royal H. Hypogonadism, hyperprolactinemia, and temporal lobe epilepsy in hyposexual men. Lancet. 1984;1:413-417.
29. Suwaidi JA, Higano ST, Holmes DR, et al. Obesity is independently associated with coronary endothelial dysfunction in patients with normal or mildly diseased coronary arteries. J Am Coll Cardiol. 2001;37:1523-1528.
30. Taub HC, Lerner SE, Melman A, Christ GJ. Relationship between contraction and relaxation in human and rabbit corpus cavernosum. Urology. 1993;42:698-704.
31. Walczak MK, Lokhandwala N, Hodge MB, Guay AT. Prevalence of cardiovascular risk factors in erectile dysfunction. J Gend Specif Med. 2002;5:19-24.